Discussion
above-the-knee
CRITICAL LIMB ISCHEMIA, BEST
We present long-term data concerning the treatment of long (almost 25 cm) and complex (94.55% occlusion) femoropopliteal lesions using drug-eluting stents (ZILVER PTX) in a controlled manner. This study demonstrates, at the very least, the non-inferiority of ZILVER PTX compared to above-the-knee prosthetic bypass. A primary patency rate of 49.3% in the ZILVER PTX group after 60 months is off course lower than the 64.9% after 5 years reported in the ZILVER PTX randomized trial [Recently, 2 multicenter, randomized controlled trials were published: the Best Endovascular versus Best Surgical Therapy for Patients with Critical Limb Ischemia (BEST-CLI) [Evidence also exists for the long-term outcomes of bypass surgery. In a prospective, randomized, multicenter study by Midy et al. [In 2018, Katsanos et al. [Recently, alongside the 3-year data from the ZILVERPASS trial, an economic analysis for Germany and the USA was published [This economic finding, coupled with the non-inferiority of Zilver PTX compared to prosthetic above-the-knee bypass at 5 years, underscores the role of an endovascular strategy with DES for TASC II C and D lesions.